Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 18, 2022 - Issue 5
Submit an article Journal homepage
3,544
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial

Christian Schwabea Auckland Clinical Studies Ltd, Auckland, New ZealandView further author information
,
Andras Illesb Biosimilars, Fresenius Kabi SwissBioSim, Eysins, SwitzerlandCorrespondence[email protected]
View further author information
,
Martin Ullmannb Biosimilars, Fresenius Kabi SwissBioSim, Eysins, SwitzerlandView further author information
,
Vishal Ghorib Biosimilars, Fresenius Kabi SwissBioSim, Eysins, SwitzerlandView further author information
,
Emmanuelle Vincentb Biosimilars, Fresenius Kabi SwissBioSim, Eysins, SwitzerlandView further author information
,
Corinne Petit-Frereb Biosimilars, Fresenius Kabi SwissBioSim, Eysins, SwitzerlandView further author information
,
Joelle Monnetb Biosimilars, Fresenius Kabi SwissBioSim, Eysins, SwitzerlandView further author information
,
Anne Sophie Racaultb Biosimilars, Fresenius Kabi SwissBioSim, Eysins, SwitzerlandView further author information
&
Chris Wynnec Christchurch Clinical Studies Trust Ltd, New ZealandView further author information
 show all
Pages 533-543 | Received 22 Dec 2021, Accepted 28 Mar 2022, Published online: 10 Apr 2022

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Kyung-Sang Yu, Byungwook Kim, Dongseong Shin, Min Kyu Park, Jun Gi Hwang, Min-Gul Kim, Hyewon Chung, JongLyul Ghim, Jae-Yong Chung, Josef S. Smolen, Gerd R. Burmester, SungHyun Kim, YunJu Bae, DaBee Jeon, JaeKyoung Yoo, GoEun Yang, JiHun Bae & Edward Keystone. (2023) Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Expert Opinion on Investigational Drugs 32:5, pages 429-439.
Read now
Monika Tomaszewska-Kiecana, Anna Dryja, Martin Ullmann, Corinne Petit-Frere, Andras Illes, Christos Dagres & Joëlle Monnet. (2023) Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults. Expert Review of Clinical Immunology 19:4, pages 447-455.
Read now
Diqin Yan, Suping Niu, Dingyuan Hu, Wenliang Dong, Yunjuan Sun, Qian Wang, Simin Wang, Qun Gu, Gang Liu, Jiaxue Wang, Liming Chen, Jie Lv, Qingshan Zheng, Haifeng Song & Yi Fang. (2023) Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose–escalation study. Expert Opinion on Investigational Drugs 32:2, pages 161-170.
Read now
Masashi Narazaki & Tadamitsu Kishimoto. (2022) Current status and prospects of IL-6–targeting therapy. Expert Review of Clinical Pharmacology 15:5, pages 575-592.
Read now

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.